European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Portfolio Pulse from Vandana Singh
Moderna Inc. (NASDAQ:MRNA) has won a significant legal victory at the European Patent Office (EPO) in its patent dispute with Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) over the COVID-19 vaccine. The EPO upheld the validity of Moderna's EP949 patent, which is crucial for its claims against Pfizer and BioNTech. Although Pfizer has nine months to appeal, this decision boosts Moderna's efforts to reclaim pandemic profits. Legal proceedings continue in multiple jurisdictions, and the financial stakes are high, with all three companies having generated significant revenue from COVID-19 vaccines in 2022.
May 17, 2024 | 4:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's victory at the EPO upholding the EP949 patent strengthens its legal position against Pfizer and BioNTech, potentially leading to financial gains from pandemic profits.
The EPO's decision to uphold Moderna's EP949 patent is a significant legal win, enhancing Moderna's claims for a share of pandemic profits. This could positively impact Moderna's stock in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
BioNTech faces a setback as the EPO upholds Moderna's EP949 patent, which could lead to financial liabilities if Moderna's claims are successful.
The EPO's decision to uphold Moderna's patent is a setback for BioNTech, potentially leading to financial liabilities. This could negatively impact BioNTech's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Pfizer faces a setback as the EPO upholds Moderna's EP949 patent, which could lead to financial liabilities if Moderna's claims are successful.
The EPO's decision to uphold Moderna's patent is a setback for Pfizer, potentially leading to financial liabilities. This could negatively impact Pfizer's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90